1. Stebbing, J. and D.A. Sanders, 2018. The importance of being earnest in post-publication review: Scientific fraud and the scourges of anonymity and excuses. Oncogene, 37: 695-696.
   CrossRef  |  Direct Link  |  
2. Soraas, L. and J. Stebbing, 2018. Geographic variation in EGFR mutation frequency in lung adenocarcinoma may be explained by interethnic genetic variation. J. Thoracic Oncol., 13: 454-458.
   CrossRef  |  PubMed  |  Direct Link  |  
3. Ottaviani, S., J. Stebbing, A.E. Frampton, S. Zagorac and J. Krell et al., 2018. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nat. Commun., Vol. 9. 10.1038/s41467-018-03962-x.
   CrossRef  |  Direct Link  |  
4. Miller, G. and J. Stebbing, 2018. Thirty years of oncogene. Oncogene, 37: 553-554.
   CrossRef  |  Direct Link  |  
5. Esteva, F.J., J. Stebbing, R.N. Wood-Horrall, P.J. Winkle, S.Y. Lee and S.J. Lee, 2018. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemother. Pharmacol., 81: 505-514.
   CrossRef  |  Direct Link  |  
6. Chandrasinghe, P., B. Cereser, M. Moorghen, I. Al Bakir and N. Tabassum et al., 2018. Role of SMAD proteins in colitis-associated cancer: From known to the unknown. Oncogene, 37: 1-7.
   CrossRef  |  Direct Link  |  
7. Carter, P., C. Alifrangis, P. Chandrasinghe, B. Cereser and L.D.B. Belluz et al., 2018. The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas. Oncotarget, 9: 11371-11376.
   CrossRef  |  Direct Link  |  
8. Carter, P., C. Alifrangis, B. Cereser, P. Chandrasinghe and L.D.B. Belluz et al., 2018. Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. Oncotarget, 9: 17589-17596.
   CrossRef  |  Direct Link  |  
9. Carter, P., C. Alifrangis, B. Cereser, P. Chandrasinghe and L.D.B. Belluz et al., 2018. Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy. Oncotarget, 9: 6007-6014.
   CrossRef  |  Direct Link  |  
10. Carter, P., C. Alifrangis, B. Cereser, P. Chandrasinghe and L.D.B. Belluz et al., 2018. Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? Oncotarget, 9: 9456-9467.
    CrossRef  |  Direct Link  |  
11. Alifrangis, C., P. Carter, B. Cereser, P. Chandrasinghe and L.D.B. Belluz et al., 2018. Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. Oncotarget, 9: 12805-12811.
    CrossRef  |  Direct Link  |  
12. Zanini, E., L.S. Louis, J. Antony, E. Karali and I.S. Okon et al., 2017. The tumor-suppressor protein OPCML potentiates anti-EGFR- and anti-HER2-targeted therapy in HER2-positive ovarian and breast cancer. Mol. Cancer Therapeut., 16: 2246-2256.
    CrossRef  |  Direct Link  |  
13. Tree, A.C., V. Harding, A. Bhangu, V. Krishnasamy and D. Morton et al., 2017. The need for multidisciplinarity in specialist training to optimize future patient care. Nat. Rev. Clin. Oncol., 14: 508-517.
    CrossRef  |  Direct Link  |  
14. Stebbing, J., Y. Baranau, V. Baryash, A. Manikhas and V. Moiseyenko et al., 2017. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: A randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol., 18: 917-928.
    CrossRef  |  Direct Link  |  
15. Shaw, J.A., D.S. Guttery, A. Hills, D. Fernandez-Garcia and K. Page et al., 2017. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin. Cancer Res., 23: 88-96.
    CrossRef  |  Direct Link  |  
16. Pinato, D.J., R. Sharma, E. Allara, C. Yen and T. Arizumi et al., 2017. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J. Hepatol., 66: 338-346.
    CrossRef  |  Direct Link  |  
17. Page, K., D.S. Guttery, D. Fernandez-Garcia, A. Hills and R.K. Hastings et al., 2017. Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer. Clin. Chem., 63: 532-541.
    CrossRef  |  Direct Link  |  
18. Neofytou, K., A. Giakoustidis, M.C. Neves, D. Morrison and D. Giakoustidis et al., 2017. Increased Carcinoembryonic Antigen (CEA) following neoadjuvant chemotherapy predicts poor prognosis in patients that undergo hepatectomy for liver-only colorectal metastases. Langenbeck's Arch. Surg., 402: 599-605.
    CrossRef  |  Direct Link  |  
19. Izumchenko, E., K. Paz, D. Ciznadija, I. Sloma and A. Katz et al., 2017. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol., 28: 2595-2605.
    CrossRef  |  Direct Link  |  
20. Harrod, A., J. Fulton, V.T. Nguyen, M. Periyasamy and L. Ramos-Garcia et al., 2017. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene, 36: 2286-2296.
    CrossRef  |  Direct Link  |  
21. Harding, V. and J. Stebbing, 2017. Liquorice: A treatment for all sorts? Lancet Oncol., 18: 1155-1155.
    CrossRef  |  Direct Link  |  
22. Craddock, C., P. Cathcart and J. Stebbing, 2017. Chilli-too hot to handle? Lancet Oncol., 18: 1005-1005.
    CrossRef  |  Direct Link  |  
23. Chandrasinghe, P., J. Stebbing and J. Warusavitarne, 2017. The MACC1-SPON2 axis: A new biomarker and therapeutic target in colorectal cancer. Oncogene, 36: 1474-1475.
    CrossRef  |  Direct Link  |  
24. Cathcart, P., C. Craddock and J. Stebbing, 2017. Fasting: Starving cancer. Lancet Oncol., 18: 431-431.
    CrossRef  |  Direct Link  |  
25. Castellano, L., A. Dabrowska, L. Pellegrino, S. Ottaviani and P. Cathcart et al., 2017. Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR. Nucleic Acids Res., 45: 4401-4412.
    CrossRef  |  Direct Link  |  
26. Boulianne, B., M.E. Robinson, P.C. May, L. Castellano and K. Blighe et al., 2017. Lineage-specific genes are prominent DNA damage hotspots during leukemic transformation of B cell precursors. Cell Rep., 18: 1687-1698.
    CrossRef  |  Direct Link  |  
27. Askari, A., S. Nachiappan, A. Currie, A. Latchford and J. Stebbing et al., 2017. The relationship between ethnicity, social deprivation and late presentation of colorectal cancer. Cancer Epidemiol., 47: 88-93.
    CrossRef  |  Direct Link  |  
28. Rampias, T., R. Favicchio, J. Stebbing and G. Giamas, 2016. Targeting tumor-stroma crosstalk: The example of the NT157 inhibitor. Oncogene, 35: 2562-2568.
    CrossRef  |  Direct Link  |  
29. Prado, M.M., A.E. Frampton, J. Stebbing and J. Krell, 2016. Single-cell sequencing in cancer research. Expert Rev. Mol. Diagn., 16: 1-5.
    CrossRef  |  Direct Link  |  
30. Pinato, D.J., S. Chowdhury and J. Stebbing, 2016. TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene, 35: 2684-2686.
    CrossRef  |  Direct Link  |  
31. Pardo, O.E., L. Castellano, C.E. Munro, Y. Hu and F. Mauri et al., 2016. miR-515-5p controls cancer cell migration through MARK4 regulation. EMBO Rep., 17: 570-584.
    CrossRef  |  Direct Link  |  
32. Oskrochi, Y., K. Razi, J. Stebbing and J. Crane, 2016. Angiosarcoma and dialysis-related arteriovenous fistulae: A comprehensive review. Eur. J. Vasc. Endovasc. Surg., 51: 127-133.
    CrossRef  |  Direct Link  |  
33. Nunes, J., H. Zhang, N. Angelopoulos, J. Chhetri and C. Osipo et al., 2016. ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget, 7: 27599-27612.
    CrossRef  |  Direct Link  |  
34. Miller, H.C., A.E. Frampton, A. Malczewska, S. Ottaviani and E.A. Stronach et al., 2016. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. Endocr.-Relat. Cancer, 23: 711-726.
    CrossRef  |  Direct Link  |  
35. Krell, J., J. Stebbing, C. Carissimi, A.F. Dabrowska and A. de Giorgio et al., 2016. TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network. Genome Res., 26: 331-341.
    CrossRef  |  Direct Link  |  
36. Jacob, J., R. Favicchio, N. Karimian, M. Mehrabi and V. Harding et al., 2016. LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. Cancer Lett., 372: 137-146.
    CrossRef  |  Direct Link  |  
37. Frampton, A.E., J. Krell, M.M. Prado, T.M. Gall and N. Abbassi-Ghadi et al., 2016. Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget, 7: 28556-28569.
    CrossRef  |  Direct Link  |  
38. Favicchio, R., C. Thepaut, H. Zhang, R. Arends, J. Stebbing and G. Giamas, 2016. Strategies in functional proteomics: Unveiling the pathways to precision oncology. Cancer Lett., 382: 86-94.
    CrossRef  |  Direct Link  |  
39. Di Giorgio, A. and J. Stebbing, 2016. Garlic: A stake through the heart of cancer? Lancet Oncol., 17: 879-880.
    CrossRef  |  Direct Link  |  
40. Coombes, R.C., L.S. Kilburn, N. Tubiana-Mathieu, T. Olmos and A. van Bochove et al., 2016. Epirubicin dose and sequential hormonal therapy-mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. Eur. J. Cancer, 60: 146-153.
    CrossRef  |  Direct Link  |  
41. Cathcart, P. and J. Stebbing, 2016. Aloe vera, a natural cancer soother? Lancet Oncol., 17: 421-421.
    CrossRef  |  Direct Link  |  
42. Brown, M., J.R. Black, R. Sharma, J. Stebbing and D.J. Pinato, 2016. Gene of the month: Axl. J. Clin. Pathol., 69: 391-397.
    CrossRef  |  Direct Link  |  
43. Balachandran, K. and J. Stebbing, 2016. Turmeric: A spice for life? Lancet Oncol., 17: 1639-1639.
    CrossRef  |  Direct Link  |  
44. Badreldin, W., J. Krell, S. Chowdhury, S.J. Harland and D. Mazhar et al., 2016. The efficacy of Irinotecan, Paclitaxel and Oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: A non-cisplatin-based induction approach. Br. J. Urol. Int., 117: 418-423.
    CrossRef  |  Direct Link  |  
45. Angelopoulos, N., J. Stebbing, Y. Xu, G. Giamas and H. Zhang, 2016. Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer. Data Brief, 7: 740-746.
    CrossRef  |  Direct Link  |  
46. Zhang, H., N. Angelopoulos, Y. Xu, A. Grothey, J. Nunes, J. Stebbing and G. Giamas, 2015. Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer. Breast Cancer Res. Treat., 151: 555-568.
    CrossRef  |  Direct Link  |  
47. Zhang, H., J. Stebbing and G. Giamas, 2015. The many-faced KSR1: A tumor suppressor in breast cancer. Oncoscience, 2: 669-670.
    CrossRef  |  Direct Link  |  
48. Xu, Y., H. Zhang, N. Angelopoulos, J. Nunes and A. Reid et al., 2015. LMTK3 represses tumor suppressor-like genes through chromatin remodeling in breast cancer. Cell Rep., 12: 837-849.
    CrossRef  |  Direct Link  |  
49. Warusavitarne, J., J. Stebbing and O. Faiz, 2015. Genetic variants and response to colon cancer treatment. Cancer, 121: 1735-1736.
    CrossRef  |  Direct Link  |  
50. Warusavitarne, J. and J. Stebbing, 2015. Probiotics and cancer: Ready for meal time? Lancet Oncol., 16: 371-372.
    CrossRef  |  Direct Link  |  
51. Stebbing, J., H. Zhang, Y. Xu, L.C. Lit and A.R. Green et al., 2015. KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. Oncogene, 34: 2103-2114.
    CrossRef  |  Direct Link  |  
52. Stebbing, J., H. Zhang, Y. Xu, A. Grothey, P. Ajuh, N. Angelopoulos and G. Giamas, 2015. Characterization of the tyrosine kinase-regulated proteome in breast cancer by combined use of RNA interference (RNAi) and stable isotope labeling with amino acids in cell culture (SILAC) quantitative proteomics. Mol. Cell. Proteomics, 14: 2479-2492.
    CrossRef  |  Direct Link  |  
53. Schofield, G., C.E. Urch, J. Stebbing and G. Giamas, 2015. When does a human being die? Quart. J. Med., 108: 605-609.
    CrossRef  |  PubMed  |  Direct Link  |  
54. Sagoo, M.S., A. Filipovic, L. Al Harby and J. Stebbing, 2015. Rare tumors: An eye on the future. Future Oncol., 11: 2641-2644.
    CrossRef  |  Direct Link  |  
55. Roca-Alonso, L., L. Castellano, A. Mills, A.F. Dabrowska and M.B. Sikkel et al., 2015. Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis. Cell Death Dis., Vol. 6. 10.1038/cddis.2015.89.
    CrossRef  |  Direct Link  |  
56. Prado, M.M., A.E. Frampton, J. Stebbing and J. Krell, 2015. Gene of the month: NANOG. J. Clin. Pathol., 68: 763-775.
    CrossRef  |  PubMed  |  Direct Link  |  
57. Pinato, D.J. and J. Stebbing, 2015. Artemisia: A divine dart against cancer? Lancet Oncol., 16: 759-760.
    CrossRef  |  Direct Link  |  
58. Nachiappan, S., A. Askari, R. Mamidanna, A. Munasinghe, A. Currie, J. Stebbing and O. Faiz, 2015. The impact of adjuvant chemotherapy timing on overall survival following colorectal cancer resection. Eur. J. Surg. Oncol., 41: 1636-1644.
    CrossRef  |  Direct Link  |  
59. Mudan, S., A. Giakoustidis, D. Morrison, S. Iosifidou, R. Raobaikady, K. Neofytou and J. Stebbing, 2015. 1000 Port-A-Cath^® placements by subclavian vein approach: Single surgeon experience. World J. Surg., 39: 328-334.
    CrossRef  |  Direct Link  |  
60. Merchant, S. and J. Stebbing, 2015. Black cohosh, hot flushes and breast cancer. Lancet Oncol., 16: 137-138.
    CrossRef  |  Direct Link  |  
61. Mapelli, P., E.O. Aboagye, J. Stebbing and R. Sharma, 2015. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene, 34: 4439-4447.
    CrossRef  |  Direct Link  |  
62. Lombardo, Y., A. de Giorgio, C.R. Coombes, J. Stebbing and L. Castellano, 2015. Mammosphere formation assay from human breast cancer tissues and cell lines. J. Visualiz. Exp., Vol. 97. 10.3791/52671.
    CrossRef  |  Direct Link  |  
63. Le Large, T.Y., A.E. Frampton, L.L. Meijer, J. Stebbing, G. Kazemier and E. Giovannetti, 2015. Usefulness of measuring microRNAs in bile and plasma for pancreatic ductal adenocarcinoma diagnosis. Am. J. Gastroenterol., 110: 768-771.
    CrossRef  |  Direct Link  |  
64. Guttery, D.S., K. Page, A. Hills, L. Woodley and S.D. Marchese et al., 2015. Noninvasive detection of activating Estrogen Receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin. Chem., 61: 974-982.
    CrossRef  |  Direct Link  |  
65. Frampton, A.E., J. Stebbing, T.M. Gall, B. Silver, L.R. Jiao and J. Krell, 2015. Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas. Expert Rev. Mol. Diagn., 15: 325-328.
    CrossRef  |  Direct Link  |  
66. Frampton, A.E., J. Krell, T.M. Gall, L. Castellano, J. Stebbing and L.R. Jiao, 2015. MIR-15b and MIR-17 are tumor-derived plasma micrornas dysregulated in colorectal neoplasia. Ann. Surg., 262: e61-e62.
    CrossRef  |  Direct Link  |  
67. Frampton, A.E., J. Krell, N.B. Jamieson, T.M. Gall and E. Giovannetti et al., 2015. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Eur. J. Cancer, 51: 1389-1404.
    CrossRef  |  Direct Link  |  
68. Cathcart, P., W. Lucchesi, S. Ottaviani, A. de Giorgio, J. Krell, J. Stebbing and L. Castellano, 2015. Noncoding RNAs and the control of signalling via nuclear receptor regulation in health and disease. Best Pract. Res. Clin. Endocrinol. Metab., 29: 529-543.
    CrossRef  |  Direct Link  |  
69. Cathcart, P., A. de Giorgio and J. Stebbing, 2015. Cannabis and cancer: Reality or pipe dream? Lancet Oncol., 16: 1291-1292.
    CrossRef  |  Direct Link  |  
70. Benhaim, L., W. Zhang, T. Wakatsuki, D. Yang and A. Gerger et al., 2015. Genetic variants of Kinase Suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer. Pharmacogenomics J., 15: 235-240.
    CrossRef  |  Direct Link  |  
71. Alshaker, H., Q. Wang, A.E. Frampton, J. Krell and J. Waxman et al., 2015. Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer. Breast Cancer Res. Treat., 149: 59-67.
    CrossRef  |  Direct Link  |  
72. Zhang, H., Y. Xu, P. Papanastasopoulos, J. Stebbing and G. Giamas, 2014. Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer. Expert Rev. Proteomics, 11: 713-731.
    CrossRef  |  Direct Link  |  
73. Winder, T., G. Giamas, P.M. Wilson, W. Zhang and D. Yang et al., 2014. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. Pharmacogenomics J., 14: 28-34.
    CrossRef  |  Direct Link  |  
74. Stebbing, J., V. Harding, C.E. Urch, T. Kaier and G. Schofield et al., 2014. The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy. Future Oncol., 10: 2555-2560.
    CrossRef  |  Direct Link  |  
75. Stebbing, J., L.C. Lit, H. Zhang, R.S. Darrington, O. Melaiu, B. Rudraraju and G. Giamas, 2014. The regulatory roles of phosphatases in cancer. Oncogene, 33: 939-953.
    CrossRef  |  Direct Link  |  
76. Stebbing, J., K. Paz, G.K. Schwartz, L.H. Wexler and R. Maki et al., 2014. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer, 120: 2006-2015.
    CrossRef  |  Direct Link  |  
77. Stebbing, J., 2014. Cancer: Where were we, where are we, where are we going. Medico-Legal J., 82: 57-66.
    CrossRef  |  Direct Link  |  
78. Shaw, J.A. and J. Stebbing, 2014. Circulating free DNA in the management of breast cancer. Ann. Transl. Med., Vol. 2, No. 1. 10.3978/j.issn.2305-5839.2013.06.06.
    CrossRef  |  Direct Link  |  
79. Sagoo, M.S., J.W. Harbour, J. Stebbing and A.M. Bowcock, 2014. Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene, 33: 4722-4723.
    CrossRef  |  Direct Link  |  
80. Pinato, D.J., R.J. Shiner, M.J. Seckl, J. Stebbing, R. Sharma and F.A. Mauri, 2014. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br. J. Cancer, 110: 1930-1935.
    CrossRef  |  Direct Link  |  
81. Pinato, D.J., G. Karamanakos, T. Arizumi, D. Adjogatse and Y.W. Kim et al., 2014. Dynamic changes of the inflammation‐based index predict mortality following chemoembolisation for hepatocellular carcinoma: A prospective study. Aliment. Pharmacol. Therapeut., 40: 1270-1281.
    CrossRef  |  Direct Link  |  
82. Papanastasopoulos, P. and J. Stebbing, 2014. Molecular basis of 5-fluorouracil-related toxicity: Lessons from clinical practice. Anticancer Res., 34: 1531-1535.
    Direct Link  |  
83. Ottaviani, S., A. de Giorgio, V. Harding, J. Stebbing and L. Castellano, 2014. Noncoding RNAs and the control of hormonal signaling via nuclear receptor regulation. J. Mol. Endocrinol., 53: R61-R70.
    CrossRef  |  Direct Link  |  
84. Melaiu, O., J. Stebbing, Y. Lombardo, E. Bracci and N. Uehara et al., 2014. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS ONE, Vol. 9. 10.1371/journal.pone.0085935.
    CrossRef  |  Direct Link  |  
85. Krell, J., A.E. Frampton, R. Mirnezami, V. Harding and A. de Giorgio et al., 2014. Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer. PLoS ONE, Vol. 9. 10.1371/journal.pone.0098561.
    CrossRef  |  Direct Link  |  
86. Krell, J. and J. Stebbing, 2014. Broader implications of a stage-guided stratified therapeutic approach for AIDS-related Kaposi's sarcoma. J. Clin. Oncol., 32: 373-375.
    CrossRef  |  PubMed  |  Direct Link  |  
87. Januszewski, A., N. Tanna and J. Stebbing, 2014. Ethnic variation in breast cancer incidence and outcomes-the debate continues. Br. J. Cancer, 110: 4-6.
    CrossRef  |  Direct Link  |  
88. Januszewski, A. and J. Stebbing, 2014. Hyperthermia in cancer: Is it coming of age? Lancet Oncol., 15: 565-566.
    CrossRef  |  Direct Link  |  
89. Hills, A. and J. Stebbing, 2014. Electrotherapy: Enlightening modern medicine. Lancet Oncol., 15: 1060-1061.
    CrossRef  |  Direct Link  |  
90. Hardt, A., J. Krell, P.D. Wilson, V. Harding and S. Chowdhury et al., 2014. Brain metastases associated with germ cell tumors may be treated with chemotherapy alone. Cancer, 120: 1639-1646.
    CrossRef  |  Direct Link  |  
91. Harding, V. and J. Stebbing, 2014. Crystals and cancer: Good vibrations or bad intentions? Lancet Oncol., 15: 263-264.
    CrossRef  |  Direct Link  |  
92. Gall, T.M., J. Jacob, A.E. Frampton, J. Krell and C. Kyriakides et al., 2014. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. JAMA Surg., 149: 482-485.
    CrossRef  |  Direct Link  |  
93. Froeling, F.E. and J. Stebbing, 2014. Uncaria tomentosa, the cat's whiskers or claws? Lancet Oncol., 15: 1299-1300.
    CrossRef  |  Direct Link  |  
94. Frampton, A.E., L. Castellano, T. Colombo, E. Giovannetti and J. Krell et al., 2014. MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology, 146: 268-277.
    CrossRef  |  Direct Link  |  
95. Frampton, A.E., E. Giovannetti, N.B. Jamieson, J. Krell and T.M. Gall et al., 2014. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Rev. Mol. Diagn., 14: 267-271.
    CrossRef  |  Direct Link  |  
96. De Giorgio, A., L. Castellano, J. Krell and J. Stebbing, 2014. Crosstalk-induced loss of miR-126 promotes angiogenesis. Oncogene, 33: 3634-3635.
    CrossRef  |  Direct Link  |  
97. Britton, D., Y. Zen, A. Quaglia, S. Selzer and V. Mitra et al., 2014. Quantification of pancreatic cancer proteome and phosphorylome: Indicates molecular events likely contributing to cancer and activity of drug targets. PLoS ONE, Vol. 9. 10.1371/journal.pone.0090948.
    CrossRef  |  Direct Link  |  
98. Bower, M. and J. Stebbing, 2014. Exploiting interleukin 6 in multicentric Castleman's disease. Lancet Oncol., 15: 910-912.
    CrossRef  |  Direct Link  |  
99. Blighe, K., L. Kenny, N. Patel, D.S. Guttery and K. Page et al., 2014. Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes. PLoS ONE, Vol. 9. 10.1371/journal.pone.0115346.
    CrossRef  |  Direct Link  |  
100. Bidard, F.C., D.J. Peeters, T. Fehm, F. Nole and R. Gisbert-Criado et al., 2014. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. Lancet Oncol., 15: 406-414.
     CrossRef  |  Direct Link  |  
101. Annels, N.E., G.R. Simpson, M. Denyer, S.E. McGrath and G. Falgari et al., 2014. Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer. Clin. Exp. Immunol., 177: 428-438.
     CrossRef  |  Direct Link  |  
102. Alshaker, H., J. Krell, A.E. Frampton, J. Waxman and O. Blyuss et al., 2014. Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway. Breast Cancer Res., Vol. 16. 10.1186/s13058-014-0426-6.
     CrossRef  |  Direct Link  |  
103. Zhang, H., Y. Xu, A. Filipovic, L.C. Lit, C.Y. Koo, J. Stebbing and G. Giamas, 2013. SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1. Br. J. Cancer, 109: 2675-2684.
     CrossRef  |  Direct Link  |  
104. Zhang, H., C.Y. Koo, J. Stebbing and G. Giamas, 2013. The dual function of KSR1: A pseudokinase and beyond. Biochem. Soc. Trans., 41: 1078-1082.
     CrossRef  |  Direct Link  |  
105. Wakatsuki, T., M.J. LaBonte, P.O. Bohanes, W. Zhang and D. Yang et al., 2013. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol. Cancer Therapeut., 12: 2261-2272.
     CrossRef  |  Direct Link  |  
106. Stebbing, J., V. Gajapathy and C. Lowdell, 2013. Chocolate: Delicious beauty or harmful beast? Lancet Oncol., 14: 457-458.
     CrossRef  |  Direct Link  |  
107. Stebbing, J., R. Payne, J. Reise, A.E. Frampton and M. Avery et al., 2013. The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: A proof-of-concept study. PLoS ONE, Vol. 8. 10.1371/journal.pone.0062543.
     CrossRef  |  Direct Link  |  
108. Stebbing, J., A. Filipovic, L.C. Lit, K. Blighe and A. Grothey et al., 2013. LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene, 32: 3371-3380.
     CrossRef  |  Direct Link  |  
109. Stebbing, J., A. Filipovic and G. Giamas, 2013. Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene, 32: 4871-4872.
     CrossRef  |  Direct Link  |  
110. Siegel, A.B. and J. Stebbing, 2013. Milk thistle: Early seeds of potential. Lancet Oncol., 14: 929-930.
     CrossRef  |  Direct Link  |  
111. Shaw, J.A., T.A. Graham and J. Stebbing, 2013. Genomic instability in pre-neoplastic colonic lesions. Oncogene, 32: 5331-5332.
     CrossRef  |  Direct Link  |  
112. Ramaswami, R. and J. Stebbing, 2013. Ginseng: Panacea among herbal remedies? Lancet Oncol., 14: 195-196.
     CrossRef  |  Direct Link  |  
113. Pohl, A., A. El-Khoueiry, D. Yang, W. Zhang and G. Lurje et al., 2013. Pharmacogenetic profiling of CD133 is associated with Response Rate (RR) and Progression-Free Survival (PFS) in patients with Metastatic Colorectal Cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J., 13: 173-180.
     CrossRef  |  Direct Link  |  
114. Pinho, F.G., A.E. Frampton, J. Nunes, J. Krell and H. Alshaker et al., 2013. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. Cancer Res., 73: 5936-5948.
     CrossRef  |  Direct Link  |  
115. Pellegrino, L., J. Stebbing, V.M. Braga, A.E. Frampton and J. Jacob et al., 2013. miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res., 41: 5400-5412.
     CrossRef  |  Direct Link  |  
116. Pellegrino, L., J. Krell, L. Roca-Alonso, J. Stebbing and L. Castellano, 2013. MicroRNA-23b regulates cellular architecture and impairs motogenic and invasive phenotypes during cancer progression. BioArchitecture, 3: 119-124.
     CrossRef  |  Direct Link  |  
117. Payne, S.J.L., J. Krell, P. Wilson, W. Ansell, A.E. Frampton, J. Stebbing and J. Shamash, 2013. The efficacy of tacrolimus and sirolimus in heavily pre-treated unresectable thymic malignancies. Lung Cancer, 80: 228-229.
     CrossRef  |  PubMed  |  Direct Link  |  
118. Papanastasopoulos, P. and J. Stebbing, 2013. Nuts and cancer: Where are we now? Lancet Oncol., 14: 1161-1162.
     CrossRef  |  Direct Link  |  
119. Page, K., D.S. Guttery, N. Zahra, L. Primrose and S.R. Elshaw et al., 2013. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS ONE, Vol. 8. 10.1371/journal.pone.0077963.
     CrossRef  |  Direct Link  |  
120. Lit, L.C., S. Scott, H. Zhang, J. Stebbing, A. Photiou and G. Giamas, 2013. LATS2 is a modulator of estrogen receptor alpha. Anticancer Res., 33: 53-63.
     Direct Link  |  
121. Lee, B., A.K. Lim, J. Krell, K. Satchithananda, R.C. Coombes, J.S. Lewis and J. Stebbing, 2013. The efficacy of axillary ultrasound in the detection of nodal metastasis in breast cancer. Am. J. Roentgenol., 200: W314-W320.
     CrossRef  |  Direct Link  |  
122. Krell, J., A.E. Frampton, T. Colombo, T.M. Gall and A. de Giorgio et al., 2013. The p53 miRNA interactome and its potential role in the cancer clinic. Epigenomics, 5: 417-428.
     CrossRef  |  Direct Link  |  
123. Krell, J., A.E. Frampton and J. Stebbing, 2013. MicroRNAs in the cancer clinic. Front. Biosci., E5: 204-213.
     CrossRef  |  PubMed  |  Direct Link  |  
124. Krell, D., P. Mulholland, A.E. Frampton, J. Krell, J. Stebbing and C. Bardella, 2013. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol., 9: 1923-1935.
     CrossRef  |  Direct Link  |  
125. Krell, D. and J. Stebbing, 2013. Aristolochia: The malignant truth. Lancet Oncol., 14: 25-26.
     CrossRef  |  Direct Link  |  
126. Harding, V., M. Afshar, J. Krell, R. Ramaswami, C.J. Twelves and J. Stebbing, 2013. 'Being there' for women with metastatic breast cancer: A pan-European patient survey. Br. J. Cancer, 109: 1543-1548.
     CrossRef  |  Direct Link  |  
127. Guttery, D.S., K. Blighe, K. Page, S.D. Marchese and A. Hills et al., 2013. Hide and seek: Tell-tale signs of breast cancer lurking in the blood. Cancer Metastasis Rev., 32: 289-302.
     CrossRef  |  Direct Link  |  
128. Gall, T.M., A.E. Frampton, J. Krell, N.A. Habib, L. Castellano, J. Stebbing and L.R. Jiao, 2013. Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: Has progress been made? Future Oncol., 9: 1861-1869.
     CrossRef  |  Direct Link  |  
129. Gall, T.M., A.E. Frampton, J. Krell, L. Castellano, J. Stebbing and L.R. Jiao, 2013. Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer. Expert Rev. Mol. Diagn., 13: 141-145.
     CrossRef  |  Direct Link  |  
130. Gall, T.M., A.E. Frampton, J. Krell, J. Jacob, J. Stebbing and L.R. Jiao, 2013. Is the detection of circulating tumor cells in locally advanced pancreatic cancer a useful prognostic marker? Expert Rev. Mol. Diagn., 13: 793-796.
     CrossRef  |  Direct Link  |  
131. Frampton, A.E., T.M. Gall, E. Giovannetti, J. Stebbing, L. Castellano, L.R. Jiao and J. Krell, 2013. Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. Expert Rev. Mol. Diagn., 13: 325-329.
     CrossRef  |  Direct Link  |  
132. Filipovic, A., J. Stebbing and G. Giamas, 2013. Cancer stem cells-therapeutic targeting or therapy? Lancet Oncol., 14: 579-580.
     CrossRef  |  Direct Link  |  
133. De Giorgio, A. and J. Stebbing, 2013. Mistletoe: for cancer or just for Christmas? Lancet Oncol., 14: 1264-1265.
     CrossRef  |  Direct Link  |  
134. Castellano, L. and J. Stebbing, 2013. Deep sequencing of small RNAs identifies canonical and non-canonical miRNA and endogenous siRNAs in mammalian somatic tissues. Nucleic Acids Res., 41: 3339-3351.
     CrossRef  |  Direct Link  |  
135. Zhang, H., A. Photiou, A. Grothey, J. Stebbing and G. Giamas, 2012. The role of pseudokinases in cancer. Cell. Signall., 24: 1173-1184.
     CrossRef  |  Direct Link  |  
136. Stebbing, J., A. Filipovic, I.O. Ellis, A.R. Green and T.R. D'Silva et al., 2012. LMTK3 expression in breast cancer: Association with tumor phenotype and clinical outcome. Breast Cancer Res. Treat., 132: 537-544.
     CrossRef  |  Direct Link  |  
137. Stebbing, J. and P. Ellis, 2012. An overview of drug development for metastatic breast cancer. Br. J. Nursing, 21: S18-S22.
     CrossRef  |  Direct Link  |  
138. Stebbing, J. and M. Bower, 2012. Cell-free DNA as a biomarker in the context of cancer, viruses and methylation. J. Infect. Dis., 205: 1032-1034.
     CrossRef  |  Direct Link  |  
139. Shaw, J.A., K. Page, K. Blighe, N. Hava and D. Guttery et al., 2012. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res., 22: 220-231.
     CrossRef  |  Direct Link  |  
140. Shavadia, J., R. Shah, G. Yonga, R. Patel, J. Stebbing and M. Nelson, 2012. The influence of antiretroviral therapy on the QTc interval in an African cohort. Clin. Infect. Dis., 54: 448-449.
     CrossRef  |  Direct Link  |  
141. Shamash, J., J. Jacob, S. Agrawal, T. Powles, K. Mutsvangwa, P. Wilson and J. Stebbing, 2012. Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: A phase 1 study. Clin. Cancer Res., 18: 2352-2359.
     CrossRef  |  Direct Link  |  
142. Roca-Alonso, L., L. Pellegrino, L. Castellano and J. Stebbing, 2012. Breast cancer treatment and adverse cardiac events: What are the molecular mechanisms? Cardiology, 122: 253-259.
     CrossRef  |  Direct Link  |  
143. Pinato, D.J., J. Stebbing, M. Ishizuka, S.A. Khan and H.S. Wasan et al., 2012. A novel and validated prognostic index in hepatocellular carcinoma: The Inflammation Based Index (IBI). J. Hepatol., 57: 1013-1020.
     CrossRef  |  Direct Link  |  
144. Pestrin, M., S. Bessi, F. Puglisi, A.M. Minisini and G. Masci et al., 2012. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res. Treat., 134: 283-289.
     CrossRef  |  Direct Link  |  
145. Payne, R.E., N.L. Hava, K. Page, K. Blighe and B. Ward et al., 2012. The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. Br. J. Cancer, 106: 375-382.
     CrossRef  |  Direct Link  |  
146. O'Cathail, S. and J. Stebbing, 2012. Ayurveda: Alternative or complementary? Lancet Oncol., 13: 865-865.
     CrossRef  |  Direct Link  |  
147. Nunes, J., M. Naymark, L. Sauer, A. Muhammad and H. Keun et al., 2012. Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection. Br. J. Cancer, 106: 909-915.
     CrossRef  |  Direct Link  |  
148. Ng, T., S. Irshad and J. Stebbing, 2012. BRCA1 mutations and luminal-basal transformation. Oncogene, 32: 2712-2714.
     CrossRef  |  Direct Link  |  
149. Krell, J., A.E. Frampton, L.R. Jiao and J. Stebbing, 2012. Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma? Pharmacogenomics, 13: 977-979.
     CrossRef  |  Direct Link  |  
150. Krell, J., A.E. Frampton, J. Jacob, L. Pellegrino and L. Roca-Alonso et al., 2012. The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis. Mol. Diagn. Ther., 16: 167-172.
     CrossRef  |  Direct Link  |  
151. Krell, J., A.E. Frampton, J. Jacob, L. Castellano and J. Stebbing, 2012. miRNAs in breast cancer: Ready for real time? Pharmacogenomics, 13: 709-719.
     CrossRef  |  Direct Link  |  
152. Krell, J., A.E. Frampton and J. Stebbing, 2012. The clinical significance of tumor infiltrating lymphoctyes in breast cancer: Does subtype matter? BMC Cancer, Vol. 12. 10.1186/1471-2407-12-135.
     CrossRef  |  Direct Link  |  
153. Krell, J. and J. Stebbing, 2012. Ginger: The root of cancer therapy? Lancet Oncol., 13: 235-236.
     CrossRef  |  Direct Link  |  
154. Krell, J. and J. Stebbing, 2012. Coffee: The science and art of moderation. Lancet Oncol., 13: 457-458.
     CrossRef  |  Direct Link  |  
155. Krell, J. and J. Stebbing, 2012. Circulating tumour cells as biomarkers in early breast cancer. Lancet Oncol., 13: 653-654.
     CrossRef  |  Direct Link  |  
156. Kitchen, D., B. Hughes, I. Gill, M. O'Brien and S. Rumbles et al., 2012. The relationship between vitamin D and chemotherapy-induced toxicity-a pilot study. Br. J. Cancer, 107: 158-160.
     CrossRef  |  Direct Link  |  
157. Keeler, B.D., J. Krell, A.G. Acheson, M.J. Brookes, J. Stebbing and A.E. Frampton, 2012. Is there a role for intravenous iron therapy in patients undergoing colorectal cancer resection? Expert Rev. Anticancer Ther., 12: 1407-1412.
     CrossRef  |  Direct Link  |  
158. Jiao, L.R., A.E. Frampton, J. Jacob, L. Pellegrino and J. Krell et al., 2012. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS ONE, Vol. 7. 10.1371/journal.pone.0032068.
     CrossRef  |  Direct Link  |  
159. Jacob, J., A.E. Frampton, L. Castellano, J. Stebbing and J. Krell, 2012. Retinoblastoma protein determines aggressiveness in triple-negative breast cancer. Expert Rev. Anticancer Ther., 12: 581-584.
     CrossRef  |  Direct Link  |  
160. Hatzimichael, E., C.L. Nigro, L. Lattanzio, N. Syed and R. Shah et al., 2012. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Br. J. Cancer, 107: 1423-1432.
     CrossRef  |  Direct Link  |  
161. Hart, C., R. Cohen, M. Norwood and J. Stebbing, 2012. The emerging harm of antioxidants in carcinogenesis. Future Oncol., 8: 535-548.
     CrossRef  |  Direct Link  |  
162. Frampton, A.E., J. Krell, Y. Zhang, J. Stebbing, L. Castellano and L.R. Jiao, 2012. The role of miR-10b in metastatic pancreatic ductal adenocarcinoma. Surgery, 152: 936-938.
     CrossRef  |  Direct Link  |  
163. Frampton, A.E., J. Krell, L. Pellegrino, L. Roca-Alonso and L.R. Jiao et al., 2012. Integrated analysis of miRNA and mRNA profiles enables target acquisition in human cancers. Expert Rev. Anticancer Ther., 12: 323-330.
     CrossRef  |  Direct Link  |  
164. Frampton, A.E., J. Krell, J. Jacob, J. Stebbing, L. Castellano and L.R. Jiao, 2012. Loss of miR-126 is crucial to pancreatic cancer progression. Expert Rev. Anticancer Ther., 12: 881-884.
     CrossRef  |  Direct Link  |  
165. Frampton, A.E., J. Krell, E. Giovannetti, L.R. Jiao and J. Stebbing, 2012. Role of miRNAs in the response to anticancer therapy. Pharmacogenomics, 13: 1663-1666.
     CrossRef  |  Direct Link  |  
166. Frampton, A.E., J. Krell, E. Giovannetti, D. Krell, J. Stebbing, L. Castellano and L.R. Jiao, 2012. Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev. Anticancer Ther., 12: 1275-1278.
     CrossRef  |  Direct Link  |  
167. Frampton, A.E. and J. Stebbing, 2012. Raising a glass of red wine against cancer, or not? Lancet Oncol., 13: 669-670.
     CrossRef  |  Direct Link  |  
168. Ezra, D.G., J. Krell, G.E. Rose, M. Bailly, J. Stebbing and L. Castellano, 2012. Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy. J. Clin. Pathol., 65: 608-613.
     CrossRef  |  Direct Link  |  
169. Coombes, R.C., T. Tat, M.L. Miller, J.A. Reise and J.L. Mansi et al., 2012. An open-label study of lapatinib in women with HER-2-negative early breast cancer: The Lapatinib Pre-Surgical study (LPS study). Ann. Oncol., 24: 924-930.
     CrossRef  |  Direct Link  |  
170. Contractor, K., E.O. Aboagye, J. Jacob, A. Challapalli, R.C. Coombes and J. Stebbing, 2012. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [¹⁸F] 3'-deoxy-3'-fluorothymidine PET: A pilot study. Biomarkers Med., 6: 231-233.
     CrossRef  |  Direct Link  |  
171. Contractor, K., A. Challapalli, G. Tomasi, L. Rosso and H. Wasan et al., 2012. Imaging of cellular proliferation in liver metastasis by [¹⁸F] fluorothymidine positron emission tomography: Effect of therapy. Phys. Med. Biol., 57: 3419-3433.
     CrossRef  |  Direct Link  |  
172. Alifrangis, C. and J. Stebbing, 2012. Shark cartilage: Has the popularisation of science failed? Lancet Oncol., 13: 22-22.
     CrossRef  |  Direct Link  |  
173. Waters, L.J., A.T. Scourfield, M. Marcano, B.G. Gazzard, M. Bower, M. Nelson and J. Stebbing, 2011. The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. Clin. Infect. Dis., 52: 671-673.
     CrossRef  |  Direct Link  |  
174. Tsim, N., A.J. Healey, A.E. Frampton, N.A. Habib and D.S. Bansi et al., 2011. Two-stage resection for bilobar colorectal liver metastases: R0 resection is the key. Ann. Surg. Oncol., 18: 1939-1946.
     CrossRef  |  Direct Link  |  
175. Stebbing, J., C. Adams, J. Krell, M. Nelson and M. Bower, 2011. HBV and lymphoma: HIV matters. AIDS, 25: 274-275.
     CrossRef  |  Direct Link  |  
176. Stebbing, J., C. Adams, A. Sanitt, S. Mletzko and M. Nelson et al., 2011. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood, 118: 271-275.
     CrossRef  |  Direct Link  |  
177. Stebbing, J., A. Thiyagarajan, V. Surendrakumar, R. Payne and J. Krell et al., 2011. Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. J. Clin. Pathol., 64: 829-831.
     CrossRef  |  Direct Link  |  
178. Stebbing, J., A. Sharma, B. North, T.J. Athersuch and A. Zebrowski et al., 2011. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann. Oncol., 23: 860-866.
     CrossRef  |  Direct Link  |  
179. Stebbing, J., A. Filipovic and G. Giamas, 2011. Lemur Tyrosine Kinase-3 (LMTK3) in cancer and evolution. Oncotarget, 2: 428-429.
     CrossRef  |  Direct Link  |  
180. Stebbing, J., A. Dalgleish, A. Gifford-Moore, A. Martin and C. Gleeson et al., 2011. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann. Oncol., 23: 1314-1319.
     CrossRef  |  Direct Link  |  
181. Stebbing, J. and C.A. Hart, 2011. Antioxidants and cancer. Lancet Oncol., 12: 996-996.
     CrossRef  |  Direct Link  |  
182. Shaw, J.A., J. Brown, R.C. Coombes, J. Jacob and R. Payne et al., 2011. Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. Biomarkers Med., 5: 87-91.
     CrossRef  |  Direct Link  |  
183. Pchejetski, D., T. Bohler, J. Stebbing and J. Waxman, 2011. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat. Rev. Urol., 8: 569-578.
184. Payne, S.J., J. Stebbing, P. Wilson and S. Slater, 2011. Outcomes in unresectable and locally advanced resected cholangiocarcinoma. Expert Rev. Anticancer Ther., 11: 705-709.
     CrossRef  |  Direct Link  |  
185. Pantanowitz, L., A. Carbone and J. Stebbing, 2011. AIDS-related pathology. Pathol. Res. Int., Vol. 2011. 10.4061/2011/437431.
     CrossRef  |  Direct Link  |  
186. Palan, M., S. Shousha and J. Stebbing, 2011. Breast cancer in the setting of HIV. Pathol. Res. Int., Vol. 2011. 10.4061/2011/925712.
     CrossRef  |  Direct Link  |  
187. Nelson, M., S. Yau, L. Baber, J. Myers and B. Ward et al., 2011. Combination antiretroviral therapy (cART) toxicities: A comparison between patients and healthcare professionals. J. Acquired Immune Deficiency Syndrome, 56: 120-122.
188. Nelson, M., S. Mackenzie, S. Yau, M. Bower, L. Waters and J. Stebbing, 2011. A comparison of patients' attitudes to antiretroviral toxicities between the UK and Uganda. AIDS, 25: 392-393.
     CrossRef  |  Direct Link  |  
189. Liu, C., J. Krishnan, J. Stebbing and X.Y. Xu, 2011. Use of mathematical models to understand anticancer drug delivery and its effect on solid tumors. Pharmacogenomics, 12: 1337-1348.
     CrossRef  |  Direct Link  |  
190. Jacob, J., J. Krell, L. Castellano, L.R. Jiao, J. Stebbing and A.E. Frampton, 2011. Determination of cut-offs for circulating tumor cell measurement in metastatic cancer. Expert Rev. Anticancer Ther., 11: 1345-1350.
     CrossRef  |  Direct Link  |  
191. Imber, C., J. Stebbing and A. Shankar, 2011. Improving outcomes in cholangiocarcinomas. Gastrointest. Cancer Res., 4: 178-179.
     PubMed  |  
192. Giamas, G., A. Filipovic, J. Jacob, W. Messier and H. Zhang et al., 2011. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat. Med., 17: 715-720.
     CrossRef  |  Direct Link  |  
193. Frampton, A.E., J. Krell, J. Jacob, J. Stebbing, L.R. Jiao and L. Castellano, 2011. microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Rev. Anticancer Ther., 11: 1837-1842.
     CrossRef  |  Direct Link  |  
194. Filipovic, A., G. Giamas and J. Stebbing, 2011. The potential role of cyclooxygenase-2 (COX-2) during early breast cancer therapy. Ann. Oncol., 22: 1700-1702.
     CrossRef  |  Direct Link  |  
195. Fallowfield, L., J. Stebbing, J. Braybrooke, C. Langridge and V. Jenkins, 2011. The preferences and experiences of different bisphosphonate treatments in women with breast cancer. Psycho-Oncology, 20: 755-761.
     CrossRef  |  Direct Link  |  
196. Dhesi, Z. and J. Stebbing, 2011. The HVTN 503/Phambili study: Efficacy is always the issue. Lancet Infect. Dis., 11: 490-491.
     CrossRef  |  Direct Link  |  
197. Contractor, K.B., L.M. Kenny, J. Stebbing, L. Rosso and R. Ahmad et al., 2011. [¹⁸F]-3′Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin. Cancer Res., 17: 7664-7672.
     CrossRef  |  Direct Link  |  
198. Contractor, K.B., L.M. Kenny, J. Stebbing, A. Challapalli and A. Al-Nahhas et al., 2011. Biological basis of [¹¹C] choline-positron emission tomography in patients with breast cancer: Comparison with [¹⁸F] fluorothymidine positron emission tomography. Nucl. Med. Commun., 32: 997-1004.
     CrossRef  |  Direct Link  |  
199. Bower, M., T. Newsom-Davis, K. Naresh, S. Merchant and B. Lee et al., 2011. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J. Clin. Oncol., 29: 2481-2486.
     CrossRef  |  PubMed  |  Direct Link  |  
200. Armstrong-James, D., J. Stebbing, L. John, A. Murungi, M. Bower, B. Gazzard and M. Nelson, 2011. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax, 66: 537-538.
     CrossRef  |  Direct Link  |  
201. Alifrangis, C., J. Krell and J. Stebbing, 2011. The pharmacoeconomics of spiralling cancer drug costs-is there a viable solution? Eur. J. Cancer, 47: 1285-1286.
     CrossRef  |  Direct Link  |  
202. Alfa-Wali, M., D. Tait, T. Allen-Mersh, P. Tekkis and M. Nelson et al., 2011. Colorectal cancer in HIV positive individuals: The immunological effects of treatment. Eur. J. Cancer, 47: 2403-2407.
     CrossRef  |  Direct Link  |  
203. Zebrowski, A., L. Wilson, A. Lim, J. Stebbing and J. Krell, 2010. Intramedullary spinal cord metastases in breast cancer are associated with improved longer-term systemic control. Future Oncol., 6: 1517-1519.
     CrossRef  |  Direct Link  |  
204. Williamson, J.M., N. Thairu, N. Katsoulas, G. Stamp and R. Ahmad et al., 2010. Impact of portal vein embolization on expression of cancer stem cell markers in regenerated liver and colorectal liver metastases. Scand. J. Gastroenterol., 45: 1472-1479.
     CrossRef  |  Direct Link  |  
205. Teague, A., C. Scott, M. Bower, B. Gazzard, M. Nelson and J. Stebbing, 2010. A single-center cohort experience of raltegravir in salvage patients failing therapy. J. Acquired Immune Deficiency Syndromes, 53: 666-667.
     CrossRef  |  Direct Link  |  
206. Stebbing, J., S.E. Krown, M. Bower, A. Batra and S. Slater et al., 2010. Primary esophageal carcinoma in the era of highly active antiretroviral therapy. Arch. Internal Med., 170: 203-207.
     CrossRef  |  Direct Link  |  
207. Stebbing, J., P. Ellis and A. Tutt, 2010. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. Future Oncol., 6: 485-486.
     CrossRef  |  Direct Link  |  
208. Stebbing, J., L. Farouk, G. Panos, M. Anderson and L.R. Jiao et al., 2010. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J. Clin. Gastroenterol., 44: 214-219.
     CrossRef  |  Direct Link  |  
209. Stebbing, J., C. Wickenden, L. Castellano, A. Sita-Lumsden and M. Nelson et al., 2010. No evidence for a polyomavirus association or aetiology in AIDS-associated nonsmall cell lung cancer. AIDS, 24: 1221-1223.
     CrossRef  |  Direct Link  |  
210. Sharma, A., S. Ngan, A. Nandoskar, C. Lowdell and J.S. Lewis et al., 2010. Schizophrenia does not adversely affect the treatment of women with breast cancer: A cohort study. Breast, 19: 410-412.
     CrossRef  |  Direct Link  |  
211. Shamash, J., J. Stebbing, C. Sweeney, G. Sonpavde and S. Harland et al., 2010. A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer, 116: 3595-3602.
     CrossRef  |  Direct Link  |  
212. Pchejetski, D., J. Nunes, L. Sauer, J. Sidhu and A. Sharma et al., 2010. Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer. Breast Cancer Res. Treat., 124: 543-549.
     CrossRef  |  Direct Link  |  
213. Mudan, S., A. Giakoustidis, A.V. Thillainayagam, J. Jacob and J. Stebbing, 2010. Clinical utility of circulating tumor cell measurement in the diagnosis of indeterminate lesions of the pancreas. Future Oncol., 6: 177-179.
     CrossRef  |  Direct Link  |  
214. Makis, A., D. Shipway, E. Hatzimichael, E. Galanakis and D. Pshezhetskiy et al., 2010. Cytokine and adhesion molecule expression evolves between the neutrophilic and lymphocytic phases of viral meningitis. J. Interferon Cytokine Res., 30: 661-665.
     CrossRef  |  Direct Link  |  
215. Lee, S., N. Syed, J. Taylor, P. Smith and B. Griffin et al., 2010. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma. Br. J. Cancer, 103: 265-274.
     CrossRef  |  Direct Link  |  
216. Krell, J., E.K. Ewart and J. Stebbing, 2010. Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer. Eur. J. Cancer, 46: 2867-2869.
     CrossRef  |  Direct Link  |  
217. Kenny, L.M., K.B. Contractor, R. Hinz, J. Stebbing and C. Palmieri et al., 2010. Reproducibility of [¹¹C]choline-positron emission tomography and effect of trastuzumab. Clin. Cancer Res., 16: 4236-4245.
     CrossRef  |  Direct Link  |  
218. Henry, N.L., D. Pchejetski, R. A'Hern, A.T. Nguyen and P. Charles et al., 2010. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study. Br. J. Cancer, 103: 291-299.
     CrossRef  |  Direct Link  |  
219. Hatzimichael, E., A. Dasoula, R. Shah, N. Syed and A. Papoudou‐Bai et al., 2010. The prolyl‐hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. Eur. J. Haematol., 84: 47-51.
     CrossRef  |  Direct Link  |  
220. Gray, K.R., K.B. Contractor, L.M. Kenny, A. Al-Nahhas and S. Shousha et al., 2010. Kinetic filtering of [¹⁸F] Fluorothymidine in positron emission tomography studies. Phys. Med. Biol., 55: 695-709.
     CrossRef  |  Direct Link  |  
221. Grant, H., X. Jiang, J. Stebbing, L. Foroni and C. Craddock et al., 2010. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. Leukemia, 24: 1817-1822.
     CrossRef  |  Direct Link  |  
222. Giamas, G., Y.L. Man, H. Hirner, J. Bischof and K. Kramer et al., 2010. Kinases as targets in the treatment of solid tumors. Cell. Signall., 22: 984-1002.
     CrossRef  |  Direct Link  |  
223. Davidson, I., H. Beardsell, B. Smith, S. Mandalia and M. Bower et al., 2010. The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH study. Antiviral Res., 86: 227-229.
     CrossRef  |  Direct Link  |  
224. D'Jaen, G.A., L. Pantanowitz, M. Bower, S. Buskin and N. Neil et al., 2010. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: A multi-institutional collaboration. Clin. Lung Cancer, 11: 396-404.
     CrossRef  |  Direct Link  |  
225. Armstrong-James, D., J. Stebbing, A. Scourfield, E. Smit and B. Ferns et al., 2010. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res., 86: 224-226.
     CrossRef  |  
226. Wickenden, C., L. Castellano, S. Rasul, J. Stebbing and L.R. Jiao, 2009. No evidence for a viral association or etiology in pancreatic carcinoma. Mol. Immunol., 47: 639-641.
227. Tuthill, M., R. Pell, R. Guiliani, A. Lim and M. Gudi et al., 2009. Peritoneal disease in breast cancer: A specific entity with an extremely poor prognosis. Eur. J. Cancer, 45: 2146-2149.
     CrossRef  |  Direct Link  |  
228. Stebbing, J., T. Powles, K. McPherson, J. Shamash and P. Wells et al., 2009. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer, 63: 94-97.
     CrossRef  |  Direct Link  |  
229. Stebbing, J., O. Duru and M. Bower, 2009. Non-AIDS-defining cancers. Curr. Opin. Infect. Dis., 22: 7-10.
     CrossRef  |  Direct Link  |  
230. Stebbing, J., N. Wong, L. Tan, A. Scourfield and L. Jiao et al., 2009. The relationship between prolonged antiretroviral therapy and cryptogenic liver disease. J. Acquired Immune Deficiency Syndromes, 50: 554-556.
     CrossRef  |  Direct Link  |  
231. Stebbing, J., A. Scourfield, G. Koh, C. Taylor and S. Taylor et al., 2009. A multicentre cohort experience with double-boosted protease inhibitors. J. Antimicrobial Chemotherapy, 64: 434-435.
     CrossRef  |  
232. Stebbing, J. and M. Bower, 2009. Epstein-Barr virus in Burkitt's lymphoma: The missing link. Lancet Oncol., 10: 430-432.
     CrossRef  |  Direct Link  |  
233. Stebbing, J. and L.R. Jiao, 2009. Circulating tumour cells as more than prognostic markers. Lancet Oncol., 10: 1138-1139.
     CrossRef  |  Direct Link  |  
234. Stebbing, J. and A. Dalgleish, 2009. The HIV-1 step study. Lancet, 373: 805-807.
235. Stebbing, J. and A. Dalgleish, 2009. Not so SMART. Lancet, 9: 268-269.
236. Slade, M.J., R. Payne, S. Riethdorf, B. Ward and S.A.A. Zaidi et al., 2009. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br. J. Cancer, 100: 160-166.
     CrossRef  |  Direct Link  |  
237. Sharma, A., S. Ngan and J. Stebbing, 2009. Psychotic illness in breast cancer. Adv. Breast Cancer, 4: 9-18.
238. Savage, P., J. Stebbing, M. Bower and T. Crook, 2009. Why does cytotoxic chemotherapy cure only some cancers? Nat. Rev. Clin. Oncol., 6: 43-52.
     CrossRef  |  Direct Link  |  
239. Powles, T., J. Stebbing, A. Bazeos, E. Hatzimichael and S. Mandalia et al., 2009. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann. Oncol., 20: 775-779.
     CrossRef  |  Direct Link  |  
240. Payne, R.E., E. Yague, M.J. Slade, C. Apostolopoulos and L.R. Jiao et al., 2009. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics, 10: 51-57.
     CrossRef  |  PubMed  |  Direct Link  |  
241. Panos, G., L. Farouk, J. Stebbing, P. Holmes and S. Valero et al., 2009. Cryptogenic pseudocirrhosis: A new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIV. J. Acquired Immune Deficiency Syndromes, 52: 525-527.
     CrossRef  |  Direct Link  |  
242. Nelson, M., T. Powles, A. Zeitlin, P. Sen and A. Scourfield et al., 2009. Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era. JAIDS J. Acquired Immune Deficiency Syndromes, 50: 113-114.
     CrossRef  |  Direct Link  |  
243. Naresh, K.N., J. Stebbing and M. Bower, 2009. Lymphoid and histiocytic proliferations in HIV-positive patients: Problems in diagnosis. J. HIV Ther., 14: 21-25.
244. McGovern, U. and J. Stebbing, 2009. Receptor-based predictors of response in breast cancer. Future Oncol., 5: 283-286.
     CrossRef  |  Direct Link  |  
245. Mahmud, M. and J. Stebbing, 2009. Epigenetic modifications in AML and MDS. Leukemia Res., 34: 139-141.
246. Lee, B., I. Franklin, J.S. Lewis, R.C. Coombes, R. Leonard, P. Gishen and J. Stebbing, 2009. The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies. Eur. J. Cancer, 45: 1597-1602.
     CrossRef  |  Direct Link  |  
247. Ledermann, J.A. and J. Stebbing, 2009. Positioning pemetrexed in the treatment of ovarian cancer. Eur. J. Cancer, 45: 1330-1332.
     CrossRef  |  Direct Link  |  
248. Keun, H.C., J. Sidhu, D. Pchejetski, J.S. Lewis and H. Marconell et al., 2009. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin. Cancer Res., 15: 6716-6723.
     CrossRef  |  PubMed  |  Direct Link  |  
249. Kenny, L.M., K.B. Contractor, J. Stebbing, A. Al-Nahhas and C. Palmieri et al., 2009. Altered tissue 3′-deoxy-3′-[¹⁸F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin. Cancer Res., 15: 6649-6657.
     CrossRef  |  Direct Link  |  
250. Jiao, L.R., C. Apostolopoulos, J. Jacob, R. Szydlo and N. Johnson et al., 2009. Unique localization of circulating tumor cells in patients with hepatic metastases. J. Clin. Oncol., 27: 6160-6165.
     CrossRef  |  PubMed  |  Direct Link  |  
251. Horlock, C., B. Stott, J. Dyson, G. Ogg and T. McPherson et al., 2009. ELISPOT and functional T cell analyses using HLA mono-specific target cells. J. Immunol. Methods, 350: 150-160.
     CrossRef  |  Direct Link  |  
252. Hatzimichael, E., L. Benetatos, A. Dasoula, G. Dranitsaris and S. Tsiara et al., 2009. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia. Leukemia Res., 33: 1272-1275.
     CrossRef  |  Direct Link  |  
253. Hatzimichael, E., G. Dranitsaris, A. Dasoula, L. Benetatos, J. Stebbing, T. Crook and K.L. Bourantas, 2009. Von Hippel-Lindau methylation status in patients with multiple myeloma: A potential predictive factor for the development of bone disease. Clin. Lymphoma Myeloma, 9: 239-242.
     CrossRef  |  Direct Link  |  
254. Giamas, G., L. Castellano, Q. Feng, U. Knippschild and J. Jacob et al., 2009. CK1δ modulates the transcriptional activity of ERα via AIB1 in an estrogen-dependent manner and regulates ERα-AIB1 interactions. Nucleic Acids Res., 37: 3110-3123.
     CrossRef  |  Direct Link  |  
255. Contractor, K.B., L.M. Kenny, J. Stebbing, A. Al-Nahhas and C. Palmieri et al., 2009. [11C] Choline positron emission tomography in estrogen receptor-positive breast cancer. Clin. Cancer Res., 15: 5503-5510.
     CrossRef  |  Direct Link  |  
256. Cohen, R., J. Stebbing and A. Windsor, 2009. Bevacizumab and surgery: What is the real risk? Future Oncol., 5: 915-917.
     CrossRef  |  Direct Link  |  
257. Castellano, L., G. Giamas, J. Jacob, R.C. Coombes and W. Lucchesi et al., 2009. The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response. Proc. Natl. Acad. Sci. USA., 106: 15732-15737.
     CrossRef  |  Direct Link  |  
258. Bower, M., O. Veraitch, R. Szydlo, P. Charles and P. Kelleher et al., 2009. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood, 113: 4521-4524.
     CrossRef  |  Direct Link  |  
259. Barker, R., F. Kazmi, J. Stebbing, S. Ngan and R. Chinn et al., 2009. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease. Eur. J. Nuclear Med. Mol. Imaging, 36: 648-652.
     CrossRef  |  Direct Link  |  
260. Annan, N.T., M. Nelson, S. Mandalia, M. Bower, B.G. Gazzard and J. Stebbing, 2009. The nucleoside backbone affects durability of efavirenz-or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J. Acquired Immune Deficiency Syndromes, 51: 140-146.
     CrossRef  |  Direct Link  |  
261. Ahamed, E., F.A. Mauri, G. Pakter, A. Lim and J. Stebbing, 2009. Trastuzumab: Unusual responses and toxicities. Future Oncol., 5: 779-784.
     CrossRef  |  Direct Link  |  
262. Windsor, A., R. Cohen, L. Jiao and J. Stebbing, 2008. Cetuximab in the first-line therapy of metastatic colorectal carcinoma: Not so CRYSTAL clear. Future Oncol., 4: 741-744.
     CrossRef  |  Direct Link  |  
263. Sullivan, R.J., L. Pantanowitz, C. Casper, J. Stebbing and B.J. Dezube, 2008. Epidemiology, pathophysiology and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma and multicentric Castleman disease. Clin. Infect. Dis., 47: 1209-1215.
     CrossRef  |  Direct Link  |  
264. Stebbing, J., T. Powles, S. Mandalia, M. Nelson, B. Gazzard and M. Bower, 2008. The use of antidepressants and risk of cancer in individuals infected with the human immunodeficiency virus. J. Clin. Oncol., 26: 2305-2310.
265. Stebbing, J., T. Powles and M. Bower, 2008. AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count. AIDS, 22: 551-552.
     CrossRef  |  Direct Link  |  
266. Stebbing, J., S. Ngan, H. Ibrahim, P. Charles and M. Nelson et al., 2008. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus‐associated multi‐centric Castleman's disease. Clin. Exp. Immunol., 154: 399-405.
     CrossRef  |  Direct Link  |  
267. Stebbing, J., M. Harrison, R. Glynne-Jones, J. Bridgewater and D. Propper, 2008. A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). Br. J. Cancer, 98: 716-719.
     CrossRef  |  Direct Link  |  
268. Stebbing, J., L. Pantanowitz, F. Dayyani, R.J. Sullivan, M. Bower and B.J. Dezube, 2008. HIV‐associated multicentric Castleman's disease. Am. J. Hematol., 83: 498-503.
269. Stebbing, J., C. Wood, M. Atkins, R. Bukowski and S. Litwin et al., 2008. Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments. Cancer, 112: 955-961.
     CrossRef  |  Direct Link  |  
270. Stebbing, J., A.K. Asghar, P. Holmes, M. Bower, H.L. Isenman and M. Nelson, 2008. Use of ezetimibe during HIV infection. J. Antimicrobial Chemotherapy, 63: 218-220.
     CrossRef  |  Direct Link  |  
271. Stebbing, J., A. Jones and P. Barrett-Lee, 2008. Cardiotoxicity and anthracyclines. Breast Cancer Res. Treat., 107: 451-453.
     CrossRef  |  Direct Link  |  
272. Powles, T., S. McFaul, J. Stebbing, P. Wilson, T. Oliver, N. Tranter and J. Shamash, 2008. The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer. OncoTargets Ther., 1: 35-39.
     Direct Link  |  
273. Powles, T., D. Robinson, J. Stebbing, J. Shamash and M. Nelson et al., 2008. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol., 27: 884-890.
     Direct Link  |  
274. Nelson, M., A. Azwa, A. Sokwala, R.S. Harania and J. Stebbing, 2008. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS, 22: 1374-1376.
     CrossRef  |  Direct Link  |  
275. Mintz, P.J., N.A. Habib, L.J. Jones, G. Giamas and J.S. Lewis et al., 2008. The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer, 113: 1489-1495.
     CrossRef  |  Direct Link  |  
276. Manek, N., C. Apostolopoulos and J. Stebbing, 2008. Progression-free versus overall survival and adequate powering in randomised studies. Eur. J. Cancer, 44: 2092-2094.
     CrossRef  |  Direct Link  |  
277. Lee, B., A. Lim, A. Lalvani, M.J.L. Descamps and R. Leonard et al., 2008. The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. Ann. Oncol., 19: 2001-2006.
     CrossRef  |  Direct Link  |  
278. Laura, W., M. Nelso, S. Mandali, M. Bowe, T. Powle, B. Gazzard and J. Stebbing, 2008. The risks and incidence of K65R and L74V mutations and subsequent virologic responses. Clin. Infect. Dis., 46: 96-100.
     CrossRef  |  Direct Link  |  
279. Jones, R., M. Nelson, M. Bower, T. Powles, S. Mandalia, B. Gazzard and J. Stebbing, 2008. Triple-class antiretroviral agent resistance in a large cohort: Prevalence and clinical outcomes. Arch. Internal Med., 168: 1926-1927.
     CrossRef  |  PubMed  |  Direct Link  |  
280. Hatzimichael, E., A. Dasoula, L. Benetatos, A. Makis and J. Stebbing et al., 2008. The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms. Br. J. Haematol., 141: 557-558.
     CrossRef  |  Direct Link  |  
281. Gaughan, E.M., B.J. Dezube, D. Aboulafia, M. Bower, J. Stebbing, T. Powles and L. Pantanowitz, 2008. Human immunodeficiency virus-associated renal cell carcinoma: A transatlantic case series. Clin. Genitourinary Cancer, 6: 86-90.
     CrossRef  |  Direct Link  |  
282. Descamps, M.J.L., H. Hyare, J. Stebbing and A. Winston, 2008. Magnetic resonance imaging and spectroscopy of the brain in HIV disease. J. HIV Ther., 13: 55-58.
     Direct Link  |  
283. Descamps, M.J., E. Hatzimichael, N. Bhuva and J. Stebbing, 2008. Radiological imaging in the context of HIV infection: size of the lesion is not everything. J. HIV Ther., 13: 47-49.
284. Cowman, S., J. Stebbing and M. Tuthill, 2008. Large bowel perforation associated with capecitabine treatment for breast cancer. Ann. Oncol., 19: 1510-1511.
     CrossRef  |  Direct Link  |  
285. Bower, M., S. Collins, C. Cottrill, K. Cwynarski and S. Montoto et al., 2008. British HIV Association guidelines for HIV‐associated malignancies 2008. HIV Med., 9: 336-388.
     CrossRef  |  Direct Link  |  
286. Bower, M., J. Stebbing, M. Tuthill, V. Campbell and J. Krell et al., 2008. Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood, 111: 3986-3990.
     CrossRef  |  Direct Link  |  
287. Apostolopoulos, C., L. Castellano, J. Stebbing and G. Giamas, 2008. Bendamustine as a model for the activity of alkylating agents. Future Oncol., 4: 323-332.
     CrossRef  |  Direct Link  |  
288. Wildfire, A., J. Stebbing and B. Gazzard, 2007. Rights theory in a specific healthcare context: Speaking ill of the dead. Postgraduate Med. J., 83: 473-477.
     CrossRef  |  Direct Link  |  
289. Wang, J., J. Stebbing and M. Bower, 2007. HIV-associated Kaposi sarcoma and gender. Gender Med., 4: 266-273.
     CrossRef  |  Direct Link  |  
290. Talor, M.V., J.H. Stone, J. Stebbing, J. Barin, N.R. Rose and C.L. Burek, 2007. Antibodies to selected minor target antigens in patients with Anti‐Neutrophil Cytoplasmic Antibodies (ANCA). Clin. Exp. Immunol., 150: 42-48.
     CrossRef  |  Direct Link  |  
291. Stebbing, J., V. Stearns and N.E. Davidson, 2007. Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics, 8: 1-3.
     CrossRef  |  Direct Link  |  
292. Stebbing, J., B. Nathan, R. Jones, A. McKenna and T. Powles et al., 2007. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS, 21: 1826-1828.
     CrossRef  |  Direct Link  |  
293. Stebbing, J., A. Sanitt, A. Teague, T. Powles, M. Nelson, B. Gazzard and M. Bower, 2007. The prognostic significance of immune cell subsets in Kaposi's sarcoma. J. Clin. Oncol., 25: 2230-2235.
294. Stebbing, J. and T. Crook, 2007. Cytotoxic-free treatment designs: Time to resistance. Nat. Clin. Pract. Oncol., Vol. 4. 10.1038/ncponc0695.
     CrossRef  |  
295. Shamash, J., T. Powles, W. Ansell, J. Stebbing and K. Mutsvangwa et al., 2007. GAMEC-a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br. J. Cancer, 97: 308-314.
     CrossRef  |  Direct Link  |  
296. Shamash, J., T. Powles, K. Mutsvangwa, P. Wilson and W. Ansell et al., 2007. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann. Oncol., 18: 925-930.
     CrossRef  |  Direct Link  |  
297. Shamash, J., J. Stebbing and T. Powles, 2007. Germ cell tumors. New Engl. J. Med., 357: 1771-1772.
298. Savage, P., M. Millrain, S. Dimakou, J. Stebbing and J. Dyson, 2007. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers. Tumor Biol., 28: 70-76.
     CrossRef  |  Direct Link  |  
299. Powles, T., P.M. Savage, J. Stebbing, D. Short and A. Young et al., 2007. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br. J. Cancer, 90: 1526-1530.
     CrossRef  |  Direct Link  |  
300. Powles, T., J. Stebbing, S. Montoto, M. Nelson and B. Gazzard et al., 2007. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood, 110: 4132-4133.
     CrossRef  |  Direct Link  |  
301. Giamas, G., J. Stebbing, C.E. Vorgias and U. Knippschild, 2007. Protein kinases as targets for cancer treatment. Pharmacogenomics, 8: 1005-1016.
     CrossRef  |  Direct Link  |  
302. Fennell, D.A., J.P. Steele, J. Shamash, M.T. Evans and P. Wells et al., 2007. Efficacy and safety of first‐or second‐line irinotecan, cisplatin and mitomycin in mesothelioma. Cancer, 109: 93-99.
     CrossRef  |  Direct Link  |  
303. Fennell, D., J.P. Steele, J. Shamash, S. Slater, M.T. Sheaff, R.M. Rudd and J. Stebbing, 2007. Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer. Int. J. Cancer, 121: 2575-2577.
     CrossRef  |  PubMed  |  Direct Link  |  
304. Davies, C.L., R. Chinn, M. Nelson, M. Rasanesan and B. Gazzard et al., 2007. Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan. Am. J. Neuroradiol., 28: 1988-1990.
     CrossRef  |  Direct Link  |  
305. Bower, M., T. Powles, S. Williams, T.N. Davis and M. Atkins et al., 2007. Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Ann. Internal Med., 147: 836-839.
     CrossRef  |  Direct Link  |  
306. Winston, A., E. Hatzimichael, V. Marvin, J. Stebbing and M. Bower, 2006. Host pharmacogenetics in the treatment of HIV and cancer. Curr. Drug Safety, 1: 107-116.
     CrossRef  |  Direct Link  |  
307. Stebbing, J., T. Powles, M. Nelson and M. Bower, 2006. Significance of variation within HIV, EBV and KSHV subtypes. J. Int. Assoc. Phys. AIDS Care, 5: 93-102.
     CrossRef  |  
308. Stebbing, J., M. Bower, S. Mandalia, M. Nelson and B. Gazzard, 2006. Highly active anti‐retroviral therapy (HAART)‐induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV‐induced mortality. Clin. Exp. Immunol., 145: 271-276.
     CrossRef  |  Direct Link  |  
309. Stebbing, J., M. Bower, P. Holmes, B. Gazzard and M. Nelson, 2006. A single centre cohort experience with a new once daily antiretroviral drug. Postgraduate Med. J., 82: 343-346.
     CrossRef  |  
310. Stebbing, J., M. Bower, N. Syed, P. Smith, V. Yu and T. Crook, 2006. Epigenetics: An emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics, 7: 747-757.
     CrossRef  |  Direct Link  |  
311. Stebbing, J., B. Gazzard and M. Bower, 2006. Host control of latent and lytic HHV-8 infection. J. Infect. Dis., 193: 1051-1053.
312. Stebbing, J., A. Sanitt, M. Nelson, T. Powles, B. Gazzard and M. Bower, 2006. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet, 367: 1495-1502.
     CrossRef  |  Direct Link  |  
313. Stebbing, J. and M. Bower, 2006. Opposing roles of dendritic cell subsets in HIV-1 infection. Blood, 108: 1785-1786.
     CrossRef  |  Direct Link  |  
314. Stebbing, J. and M. Bower, 2006. Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. Lancet Oncol., 7: 61-68.
     CrossRef  |  Direct Link  |  
315. Powles, T., D. Macdonald, M. Nelson and J. Stebbing, 2006. Hepatocellular cancer in HIV-infected individuals: Tomorrow's problem? Expert Rev. Anticancer Ther., 6: 1553-1558.
     CrossRef  |  Direct Link  |  
316. Powles, T., A. Young, A. Sanitt, J. Stebbing and D. Short et al., 2006. The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. Br. J. Cancer, 95: 727-737.
     CrossRef  |  Direct Link  |  
317. Pollock, K., J. Stebbing, M. Bower, B. Gazzard and M. Nelson, 2006. Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: A method of assessing toxicity. J. Antimicrobial Chemotherapy, 58: 227-228.
     CrossRef  |  Direct Link  |  
318. Mazhar, D., J. Stebbing, R. Lewis, M. Nelson, B.G. Gazzard and M. Bower, 2006. The management of meningeal lymphoma in patients with HIV in the era of HAART: Intrathecal depot cytarabine is effective and safe. Blood, 107: 3412-3414.
     CrossRef  |  Direct Link  |  
319. Mazhar, D., J. Stebbing and W. Heller, 2006. Recent advances in the systemic management of colorectal cancer. Future Oncol., 2: 643-650.
     CrossRef  |  
320. Mazhar, D., J. Stebbing and M. Bower, 2006. Non-Hodgkin's lymphoma and the CNS: Prophylaxis and therapy in immunocompetent and HIV-positive individuals. Expert Rev. Anticancer Ther., 6: 335-341.
     CrossRef  |  Direct Link  |  
321. Mazhar, D., J. Stebbing and M. Bower, 2006. Chemotherapy for advanced cholangiocarcinoma: What is standard treatment. Future Oncol., 2: 509-514.
     CrossRef  |  Direct Link  |  
322. Makis, A.C., E.C. Hatzimichael, J. Stebbing and K.L. Bourantas, 2006. C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease. Arch. Internal Med., 166: 366-368.
     CrossRef  |  Direct Link  |  
323. Makis, A.C., E.C. Hatzimichael and J. Stebbing, 2006. The genomics of new drugs in sickle cell disease. Pharmacogenomics, 7: 909-917.
     CrossRef  |  
324. Hatzimichael, E., L. Benetatos, J. Stebbing, E. Kapsali, S. Panayiotopoulou and K.L. Bourantas, 2006. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. Int. J. Laboratory Hematol., 28: 416-418.
     CrossRef  |  Direct Link  |  
325. Bower, M., T. Powles, M. Nelson, S. Mandalia, B. Gazzard and J. Stebbing, 2006. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J. Nat. Cancer Inst., 98: 1088-1091.
     CrossRef  |  Direct Link  |  
326. Bower, M., D. Mazhar and J. Stebbing, 2006. Should cervical cancer be an acquired immunodeficiency syndrome-defining cancer? J. Clin. Oncol., 24: 2417-2419.
     CrossRef  |  PubMed  |  Direct Link  |  
327. Bowen, R.L., J. Stebbing and L.J. Jones, 2006. A review of the ethnic differences in breast cancer. Pharmacogenomics, 7: 935-942.
     CrossRef  |  PubMed  |  Direct Link  |  
328. Woolfson, A., J. Stebbing, B.D. Tom, K.J. Stoner and W.R. Gilks et al., 2005. Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals. Blood, 106: 1003-1007.
     CrossRef  |  Direct Link  |  
329. Waters, L., J. Stebbing, S. Mandalia, A.M. Young, M. Nelson, B. Gazzard and M. Bower, 2005. Hepatitis C infection is not associated with systemic HIV‐associated non‐hodgkin's lymphoma: A cohort study. Int. J. Cancer, 116: 161-163.
     CrossRef  |  Direct Link  |  
330. Waters, L., J. Stebbing, R. Jones, S. Mandalia and M. Bower et al., 2005. The effect of statins on HIV rebound and blips. J. Acquired Immune Deficiency Syndromes, 39: 637-638.
     CrossRef  |  Direct Link  |  
331. Walter, N.A.R., J. Stebbing and W. Messier, 2005. The potential significance of adaptive evolution and dimerization in chimpanzee intercellular cell adhesion molecules (ICAMs). J. Theor. Biol., 232: 339-346.
     CrossRef  |  Direct Link  |  
332. Stebbing, J., S. Sawleshwarkar, C. Michailidis, R. Jones and M. Bower et al., 2005. Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgraduate Med. J., 81: 586-588.
     CrossRef  |  Direct Link  |  
333. Stebbing, J., S. Mandalia, C. Palmieri, M. Nelson, B. Gazzard and M. Bower, 2005. Burkitt’s lymphoma and prior AIDS-defining illnesses are not prognostic factors in AIDS-related non Hodgkin’s lymphoma. J. Clin. Oncol., 23: 8538-8540.
334. Stebbing, J., L. Waters, S. Mandalia, M. Bower, M. Nelson and B. Gazzard, 2005. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin. Infect. Dis., 41: 906-911.
     CrossRef  |  Direct Link  |  
335. Stebbing, J., L. Waters, L. Davies, S. Mandalia, M. Nelson, B. Gazzard and M. Bower, 2005. Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study. J. Clin. Oncol., 23: 8134-8136.
336. Stebbing, J., D. Mazhar, R. Lewis, C. Palmieri and E. Hatzimichael et al., 2005. The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma. Ann. Oncol., 17: 503-506.
     CrossRef  |  Direct Link  |  
337. Stebbing, J., B. Gazzard and M. Bower, 2005. The role of CD91 and HSPs in psoriasis. Br. J. Dermatol., 152: 1095-1097.
338. Panteli, K.E., E.C. Hatzimichael, P.K. Bouranta, A. Katsaraki, K. Seferiadis, J. Stebbing and K.L. Bourantas, 2005. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br. J. Haematol., 130: 709-715.
     CrossRef  |  Direct Link  |  
339. Orkin, C., J. Stebbing, M. Nelson, M. Bower and M. Johnson et al., 2005. A randomized study comparing a three-and four-drug HAART regimen in first-line therapy (QUAD study). J. Antimicrob. Chemother., 55: 246-251.
     CrossRef  |  Direct Link  |  
340. Latham, V., J. Stebbing, S. Mandalia, C. Michailidis and E. Davies et al., 2005. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J. Antimicrob. Chemother., 56: 186-189.
     CrossRef  |  Direct Link  |  
341. Kebba, A., J. Stebbing, S. Rowland, R. Ingram and J. Agaba et al., 2005. Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects. J. Leukocyte Biol., 78: 37-42.
     Direct Link  |  
342. Jones, R., S. Sawleshwarkar, C. Michailidis, A. Jackson and S. Mandalia et al., 2005. Impact of antiretroviral choice on hypercholesterolaemia events: The role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med., 6: 396-402.
     CrossRef  |  Direct Link  |  
343. Fox, P.A., J.E. Seet, J. Stebbing, N. Francis and S.E. Barton et al., 2005. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: A review of cases from an anoscopy clinic. Sexually Transmitted Infect., 81: 142-146.
     CrossRef  |  Direct Link  |  
344. Cackett, P., M. Bower and J. Stebbing, 2005. Isolated conjunctival lymphoma metastasis from previous low grade non-Hodgkin’s lymphoma. Postgraduate Med. J., Vol. 81. 10.1136/pgmj.2004.026344.
     CrossRef  |  Direct Link  |  
345. Cackett, P. and J. Stebbing, 2005. Transorbital brain injuries. Emerg. Med. J., 22: 299-301.
     CrossRef  |  Direct Link  |  
346. Bower, M., T. Powles, J. Stebbing and C. Thirlwell, 2005. Potential antiretroviral drug interactions with cyclophosphamide, Doxorubicin and Etoposide. J. Clin. Oncol., 23: 1328-1329.
     CrossRef  |  Direct Link  |  
347. Bower, M., M. Nelson, A.M. Young, C. Thirlwell and T. Newsom-Davis et al., 2005. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J. Clin. Oncol., 23: 5224-5228.
     CrossRef  |  PubMed  |  Direct Link  |  
348. Bower, M., B. Gazzard, S. Mandalia, T. Newsom-Davis and C. Thirlwell et al., 2005. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann. Internal Med., 143: 265-273.
     CrossRef  |  Direct Link  |  
349. Waters, L., J. Stebbing, R. Jones, C. Michailidis and S. Sawleshwarkar et al., 2004. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J. Antimicrob. Chemother., 54: 503-507.
     CrossRef  |  Direct Link  |  
350. Stebbing, J., V. Marvin and M. Bower, 2004. The evidence-based treatment of AIDS-related non-Hodgkin’s lymphoma. Cancer Treat. Rev., 30: 249-253.
     CrossRef  |  Direct Link  |  
351. Stebbing, J., T. Powles, R. Glassman, V. Marvin and M. Bower, 2004. The prevention of AIDS-related malignancies. Int. J. Cancer Prev., 1: 89-97.
352. Stebbing, J., S. Portsmouth, M. Nelson, S. Mandalia and H. Kandil et al., 2004. The efficacy of ritonavir in the prevention of AIDS‐related Kaposi's sarcoma. Int. J. Cancer, 108: 631-633.
     CrossRef  |  Direct Link  |  
353. Stebbing, J., S. Patterson, S. Portsmouth, C. Thomas and R. Glassman et al., 2004. Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients. Cell Res., 14: 251-256.
     CrossRef  |  Direct Link  |  
354. Stebbing, J., S. Mandalia, S. Portsmouth, P. Leonard and J. Crane et al., 2004. A questionnaire survey of stress and bullying in doctors undertaking research. Postgraduate Med. J., 80: 93-96.
     CrossRef  |  Direct Link  |  
355. Stebbing, J., M. Bower, B. Gazzard, A. Wildfire, H. Pandha, A. Dalgleish and J. Spicer, 2004. The common heat shock protein receptor CD91 is up‐regulated on monocytes of advanced melanoma slow progressors. Clin. Exp. Immunol., 138: 312-316.
     CrossRef  |  Direct Link  |  
356. Stebbing, J., M. Bower and P. Srivastava, 2004. Kaposi's sarcoma as a model for cancer immunotherapy. Trends Mol. Med., 10: 187-193.
     CrossRef  |  Direct Link  |  
357. Stebbing, J., M. Atkins, M. Nelson, S. Rajpopat, T. Newsom-Davis, B. Gazzard and M. Bower, 2004. Hepatitis B reactivation during combination chemotherapy for AIDS-related lymphoma is uncommon and does not adversely affect outcome. Blood, 103: 2431-2432.
     CrossRef  |  Direct Link  |  
358. Stebbing, J., B. Gazzard, T. Newsom‐Davis, M. Nelson and S. Patterson et al., 2004. Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. Int. J. Cancer, 108: 473-474.
     CrossRef  |  PubMed  |  Direct Link  |  
359. Stebbing, J., B. Gazzard, S. Patterson, M. Bower and M. Nelson et al., 2004. One step fusion protein directed expansion of CTLs. AIDS, 18: 2099-3001.
360. Stebbing, J., B. Gazzard, S. Patterson, M. Bower and D. Perumal et al., 2004. Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: A new approach to therapeutic vaccination. Blood, 103: 1791-1795.
     CrossRef  |  Direct Link  |  
361. Stebbing, J., B. Gazzard, S. Mandalia, A. Teague and A. Waterston et al., 2004. Anti-retroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin’s lymphoma. J. Clin. Oncol., 22: 2177-2183.
362. Stebbing, J., B. Gazzard and D. Douek, 2004. Sanctuary sites of HIV in vivo. New Engl. J. Med., 350: 1872-1880.
363. Powles, T., M. Bower, J. Shamash, J. Stebbing and J. Ong et al., 2004. Outcome of patients with HIV-related germ cell tumours: A case-control study. Br. J. Cancer, 90: 1526-1530.
     CrossRef  |  Direct Link  |  
364. Portsmouth, S., N. Imami, J. Stebbing, A. Pires, M. Nelson and B. Gazzard, 2004. The clinical and therapeutic effects of HAART administered to HIV-1 seroconverters. HIV Med., 5: 26-29.
365. Newsom-Davis, T., M. Bower, A. Wildfire, C. Thirlwell, M. Nelson, B. Gazzard and J. Stebbing, 2004. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-α levels. Leukemia Lymphoma, 45: 1939-1941.
     CrossRef  |  Direct Link  |  
366. Jones, R., J. Stebbing, M. Nelson, G. Moyle, M. Bower, S. Mandalia and B. Gazzard, 2004. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J. Acquired Immune Deficiency Syndromes, 37: 1489-1495.
     CrossRef  |  Direct Link  |  
367. Greenspan, G., D. Geiger, F. Gotch, M. Bower and S. Patterson et al., 2004. Recombination does not occur in newly identified diverged oceanic picornaviruses. J. Mol. Evol., 58: 359-360.
     CrossRef  |  Direct Link  |  
368. Greenspan, G., D. Geiger, F. Gotch, M. Bower and S. Patterson et al., 2004. Model-based inference of recombination hotspots in a highly, variable oncogene. J. Mol. Evol., 58: 239-251.
     CrossRef  |  Direct Link  |  
369. Donaghy, H., J. Stebbing and S. Patterson, 2004. Antigen presentation and the role of dendritic cells in HIV. Curr. Opin. Infect. Dis., 17: 1-6.
     Direct Link  |  
370. Bower, M., T. Powles, T. Newsom-Davis, C. Thirlwell and J. Stebbing et al., 2004. HIV-associated anal cancer: Has highly active antiretroviral therapy reduced the incidence or improved the outcome? J. Acquired Immune Deficiency Syndromes, 37: 1563-1565.
     Direct Link  |  
371. Bower, M., N. McCall-Peat, N. Ryan, L. Davies and A.M. Young et al., 2004. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood, 104: 2943-2946.
     CrossRef  |  Direct Link  |  
372. Thomas, C., M. Nelson and J. Stebbing, 2003. HIV and hepatitis B: A review. AIDS Patient Care STDs, 17: 623-633.
     CrossRef  |  Direct Link  |  
373. Thirlwell, C., D. Sarker, J. Stebbing and M. Bower, 2003. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin. Lymphoma, 4: 86-92.
     CrossRef  |  Direct Link  |  
374. Stebbing, J., S. Portsmouth, P. Fox, C. Brock and M. Bower, 2003. Multiple human papillomavirus types appear to be a feature of anal not cervical intra-epithelial neoplasia. Aids, 17: 2401-2401.
     Direct Link  |  
375. Stebbing, J., S. Portsmouth, F. Gotch and B. Gazzard, 2003. Kaposi's sarcoma-an update. Int. J. STD Aids, 14: 225-227.
     CrossRef  |  Direct Link  |  
376. Stebbing, J., S. Portsmouth and M. Bower, 2003. Insights into the molecular biology and sero-epidemiology of Kaposi's sarcoma. Curr. Opin. Infect. Dis., 16: 25-31.
     Direct Link  |  
377. Stebbing, J., S. Portsmouth and B. Gazzard, 2003. Virus-host interactions. Obstet. Gynecol., 5: 46-49.
378. Stebbing, J., S. Patterson and F. Gotch, 2003. New insights into the immunology and evolution of HIV. Cell Res., 13: 1-7.
     CrossRef  |  Direct Link  |  
379. Stebbing, J., D. Bourloulia, M. Johnson, S. Henderson, I. Williams and N. Wilder, 2003. KSHV specific CTLs recognize and target Darwinian positively selected autologous K1 epitopes. J. Virol., 77: 4306-4314.
380. Stebbing, J., B. Gazzard, S. Portsmouth, F. Gotch and L. Kim et al., 2003. Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood, 102: 1806-1814.
     CrossRef  |  Direct Link  |  
381. Stebbing, J., B. Gazzard, O. Flore, C. Thomas and A. Benlahrech et al., 2003. Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. Aids, 17:: 1988-2000.
     Direct Link  |  
382. Stebbing, J., B. Gazzard, L. Kim, S. Portsmouth and A. Wildfire et al., 2003. The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected “true” long-term nonprogressors. Blood, 101: 4000-4004.
     CrossRef  |  Direct Link  |  
383. Stebbing, J., A. Wildfire, S. Portsmouth, T. Powles and C. Thirlwell et al., 2003. Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: Clinical and angiogenic correlations. Ann. Oncol., 14: 1660-1666.
     CrossRef  |  Direct Link  |  
384. Stebbing, J. and M. Bower, 2003. What can oncologists learn from HIV? Lancet Oncol., 4: 438-445.
     CrossRef  |  Direct Link  |  
385. Stebbing, J. and G. Moyle, 2003. The clades of HIV: Their origins and clinical significance. AIDS Rev., 5: 205-213.
     PubMed  |  
386. Stebbing, J. and B.G. Gazzard, 2003. Clinical utility of resistance testing. J. HIV Therapy, 7: 75-80.
387. Stebbing, J. and B. Gazzard, 2003. Stemming the HIV epidemic: Prevention and therapy go hand-in-hand. J. HIV Therapy, 8: 51-55.
388. Stebbing, J. and B. Gazzard, 2003. Brucella induced autoimmune hepatitis: Causal or a mere association? Int. J. Clin. Pract., 57: 565-567.
389. Powles, T., M. Bower, G. Daugaard, J. Shamash and A. de Ruiter et al., 2003. Multicenter study of human immunodeficiency virus-related germ cell tumors. J. Clin. Oncol., 21: 1922-1927.
     CrossRef  |  Direct Link  |  
390. Portsmouth, S., J. Stebbing, X. Keyi, J. Zhang and G. Pi, 2003. HIV and AIDS in the people’s republic of China: A collaborative review. Int. J. STD Aids, 14: 757-763.
     CrossRef  |  Direct Link  |  
391. Portsmouth, S., J. Stebbing, J. Gill, S. Mandalia, M. Nelson, M. Bower and B. Gazzard, 2003. A comparison of regimens based on NNRTI and PIs in preventing Kaposi’s sarcoma. Aids, 17: F17-F22.
392. Portsmouth, S., J. Stebbing and B. Gazzard, 2003. Current treatment for HIV-1 infection. Curr. Topics Med. Chem., 3: 1458-1466.
393. Portsmouth, S., H. Kandil, B. Gazzard and J. Stebbing, 2003. The innate and adaptive immunology of HIV. Int. J. STD Aids, 14: 652-655.
394. Nelson, M., S. Portsmouth, J. Stebbing, A. Barr and G. Matthews et al., 2003. An open-label study of tenofovir in human immunodeficiency virus-1 and hepatitis B co-infected individuals. Aids, 17: F7-F10.
395. Lubis, N., D. Baylis, A. Short, J. Stebbing and A. Teague et al., 2003. Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia. Postgraduate Med. J., 79: 164-166.
     CrossRef  |  Direct Link  |  
396. Kandil, H., J. Stebbing, B. Gazzard and S. Portsmouth, 2003. Innate and adaptive immunological insights into HIV pathogenesis. Int. J. STD AIDS, 14: 652-655.
     CrossRef  |  Direct Link  |  
397. Gazzard, B.G., A.L. Pozniak, W. Rosenbaum, G.P. Yeni and S. Staszewski et al., 2003. An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. Aids, 17: F49-F54.
     Direct Link  |  
398. Fox, P., J. Stebbing, S. Portsmouth, A. Winston and N. Frances et al., 2003. Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy. Aids, 17: 279-280.
     Direct Link  |  
399. Datta, D., B. Gazzard and J. Stebbing, 2003. The diagnostic yield of stool analysis in 525 HIV-1-infected individuals. Aids, 17: 1711-1713.
     Direct Link  |  
400. Cackett, P., J. Stebbing and B. Dillon, 2003. Complications of therapy and a diagnostic dilemma case. Case 1. Radiation maculopathy following treatment of nasopharyngeal carcinoma. J. Clin. Oncol., 21: 4650-4651.
     CrossRef  |  PubMed  |  Direct Link  |  
401. Allen, S.H., P. Brennan-Benson, M. Nelson, D. Asboe and M. Bower et al., 2003. Pneumonia due to antibiotic resistant Streptococcus pneumonia and Pseudomonas aeruginosa in the HAART era. Postgraduate Med. J., 79: 691-694.
     Direct Link  |  
402. Stebbing, J., J. Crane, A.S. Greenstein and D.G. Ezra, 2002. Atypical metastases from squamous cell cancers. Grand Rounds, 2: 43-45.
     CrossRef  |  Direct Link  |  
403. Stebbing, J. and A. Gaya, 2002. Pegylated liposomal doxorubicin (Caelyx®) in advanced ovarian cancer. Cancer Treat. Rev., 28: 121-128.
404. Gaya, A., J. Rees, A.S. Greenstein and J. Stebbing, 2002. The use of temozolomide in recurrent malignant gliomas. Cancer Treat. Rev., 28: 115-120.
     CrossRef  |  Direct Link  |  
405. Stebbing, J., N. Wilder, S. Ariad and M. Abu‐Shakra, 2001. Lack of intra‐patient strain variability during infection with Kaposi's sarcoma‐associated herpesvirus. Am. J. Hematol., 68: 133-134.
     CrossRef  |  Direct Link  |  
406. Stebbing, J., M. Thomas and M. Gore, 2001. Necrosis in melanoma metastases with treatment. Ann. Oncol., 12: 873-874.
     CrossRef  |  Direct Link  |  
407. Stebbing, J., C. Benson, T. Eisen, L. Pyle and K. Smalley et al., 2001. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer, 85: 953-958.
     CrossRef  |  Direct Link  |  
408. Stebbing, J. and S. O’Reilly, 2001. Herceptin: From bench to media to bedside. CME Breast, 1: 4-6.
409. Stebbing, J. and M. Gore, 2001. The current status of interferon‐α treatment in advanced renal cancer. BJU Int., 87: 599-601.
     CrossRef  |  Direct Link  |  
410. Stebbing, J. and A. Gaya, 2001. The evidence-based use of induction chemotherapy in breast cancer. Breast Cancer, 8: 23-37.
     CrossRef  |  PubMed  |  Direct Link  |  
411. Saunders, Y., J. Stebbing, K. Broadley and S.R.D. Johnston, 2001. Recurrent locally advanced breast cancer: The treatment of chest wall disease with further chemotherapy. Clin. Oncol., 13: 195-199.
     CrossRef  |  Direct Link  |  
412. Ng, C., J. Stebbing and I. Judson, 2001. Cardiac metastasis from a myxoid liposarcoma. Clin. Oncol., 13: 384-385.
     CrossRef  |  Direct Link  |  
413. Stone, J.H., M. Talor, J. Stebbing, M.L. Uhlfelder and N.R. Rose et al., 2000. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA‐associated conditions. Arthritis Care Res., 13: 424-434.
     CrossRef  |  Direct Link  |  
414. Stebbing, J., E. Copson, N. Al-Nasiri and G.P.H. Giu, 2000. A pregnant breast lump. Lancet, 356: 396-396.
     CrossRef  |  Direct Link  |  
415. Stebbing, J., E. Copson and S. O’Reilly, 2000. Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat. Rev., 26: 287-290.
     CrossRef  |  Direct Link  |  
416. Stebbing, J., 2000. Breast cancer-22nd annual symposium. Invest. Drugs, 3: 289-291.
417. Stebbing, J. and R.K. Gregory, 2000. The use of HRT in patients with breast cancer: Yes, no, or sometimes? Br. J. Gen. Pract., 50: 356-359.
     Direct Link  |  
418. Stebbing, J. and M. Gore, 2000. The dosing and schedule of cytotoxics in ovarian cancer. CME J. Gynecol., 3: 362-364.
419. Stebbing, J. and I.E. Smith, 2000. Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration. Clin. Oncol., 12: 326-327.
     CrossRef  |  Direct Link  |  
420. Stebbing, J., O. Buetens, D. Hellmann and J. Stone, 1999. Secondary amyloidosis associated with giant cell arteritis/polymyalgia rheumatica. J. Rheumatol., 26: 2698-2700.
     PubMed  |  
421. Stebbing, J., F. Askin, E. Fishman and J. Stone, 1999. Pulmonary manifestations of ulcerative colitis mimicking Wegener's granulomatosis. J. Rheumatol., 26: 1617-1621.
     PubMed  |  
422. Stebbing, J., D.G. Ezra, P.D. Cackett and A.S. Greenstein, 1999. The treatment of ascites and apparent renal failure with foley catheters. J. Royal Soc. Med., 92: 582-583.
423. Noussari, H.C., A. Kimyai-Asadi, J. Stebbing and J.H. Stone, 1999. Purple toes in a patient with end-stage rheumatoid arthritis. Arch. Dermatol., 135: 648-650.
     CrossRef  |  Direct Link  |  
424. Kaplan, D.E. and J. Stebbing, 1999. Livedo reticularis: A review. Osler Med. J., 5: 12-18.
425. Stebbing, J., 1998. Studs, the ordernet and peer review. J. R. Soc. Med., 91: 652-653.
     CrossRef  |  Direct Link  |  
426. Stebbing, J. and J.I. Wyatt, 1998. Gastric ‘pseudolipomatosis’. Histopathology, 32: 283-284.
     PubMed  |  
427. Stebbing, J., 1997. Too much life on earth? Q. J. Med., 90: 597-599.
     Direct Link  |  
428. Stebbing, J., 1997. Post-prandial syncope due to nitrates in food. Postgraduate Med. J., 73: 606-608.
     Direct Link  |  
429. Stebbing, J., H.L. Simmons and J. Hepple, 1995. Deliberate self-harm using yew leaves (Taxus baccata). Br. J. Clin. Pract., 49: 101-102.
     PubMed  |  
430. Stebbing, J., 1995. The cholesterol emboli syndrome. Br. J. Clin. Pract., 49: 108-110.
431. Stebbing, J. and J. Barnett, 1994. The foraging patterns of Camponotus spp. in Kinglake national park. Aust. J. Zool., 18: 256-258.